82 FR 221 pgs. 54386-54387 - Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability; Correction
Type: NOTICEVolume: 82Number: 221Pages: 54386 - 54387
Pages: 54386, 54387Docket number: [Docket No. FDA-2014-D-1167]
FR document: [FR Doc. 2017-24948 Filed 11-16-17; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-D-1167]
Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability; Correction
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice; correction.
SUMMARY:
[top] The Food and Drug Administration is correcting a notice entitled "Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability" that appeared in the
FOR FURTHER INFORMATION CONTACT:
Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave. Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115, lisa.granger@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
In the Federal Register of Friday, November 3, 2017 (82 FR 51277), in FR Doc. 2017-23947, the following correction is made:
On page 51277, in the second column, in the header of the document, "[Docket FDA-2014-D-1147]" is corrected to read "[Docket No. FDA-2014-D-1167]".
Dated: November 9, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-24948 Filed 11-16-17; 8:45 am]
BILLING CODE 4164-01-P